Hanan Nazir
Sultan Qaboos University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hanan Nazir.
Pediatric Blood & Cancer | 2017
Hanan Nazir; Amna Al-Futaisi; Mathew Zacharia; Mohamed Elshinawy; Surekha Tony Mevada; Abdulhakim Al-Rawas; Doaa Khater; Deepali Jaju; Yasser Wali
Vincristine (VCR) induced peripheral neuropathy is a common complication in children with acute lymphoblastic leukemia (ALL).
Journal of Pediatric Hematology Oncology | 2017
Hanan Nazir; Mohamed Elshinawy; Abdulhakim Al-Rawas; Doaa Khater; Sherin Zadjaly; Yasser Wali
Study Objective: To study dapsone in comparison with trimethoprim/sulfamethoxazole (TMP/SMX) for Pneumocystis jiroveci (PJP) prophylaxis in children with acute lymphoblastic leukemia (ALL). Design: A retrospective study with a prospective follow-up. Patients: Pediatric ALL patients diagnosed between May 2009 and May 2014, who are still receiving or have completed their maintenance chemotherapy. Patients who completed chemotherapy were prospectively followed up for neutropenia. Methods: TMP/SMX was used as the initial PJP prophylaxis. An alternative drug was indicated if the patient remained cytopenic for >3 weeks. Average absolute neutrophilic count (ANC), average % of oral mercaptopurine (6-MP), and methotrexate doses were calculated over a period of 6 months before and after shifting to dapsone. Results: Sixty-two ALL patients were eligible for analysis. Twenty-four patients (38.7%) received TMP/SMX for PJP prophylaxis, whereas 34 patients received Dapsone (54.8%). Only 3 patients received IV pentamidine (4.8%), whereas 1 patient (1.6%) received atovaquone. The incidence of prophylaxis failure was 1/1041 months on TMP/SMX and 1/528 months on dapsone. After shifting to dapsone, patients maintained significantly higher ANC (1.46±0.46 vs. 1.17±0.40, P=0.0053), and received significantly higher doses of 6-MP (62.61%±11.45 vs. 57.45±10.14, P=0.0081) and methotrexate (64.9%±14.29 vs. 56.5%±9.9, P=0.0176), with a significantly shorter duration of chemotherapy interruption (1.94±1.2 vs. 3.25±1.29 wk, P=0.0002). Conclusions: Dapsone for PJP prophylaxis in ALL allowed patients to maintain higher ANC and to receive higher doses of chemotherapy, while maintaining a low incidence of PJP breakthrough infection.
Clinical and Applied Thrombosis-Hemostasis | 2018
Mohamed Rachid Boulassel; Maryam Al-Ghonimi; Badriya Al-Balushi; Amal Al-Naamani; Zahra Al-Qarni; Yasser Wali; Mohamed Elshinawy; Maryam Al-Shezawi; Hamad Khan; Hanan Nazir; Doaa Khater; Anil Pathare; Salam Alkindi
Development of inhibitors remains a major clinical complication in patients with hemophilia A receiving replacement therapy with factor VIII (FVIII). Understanding the immune mechanisms involved in the development of inhibitors can provide valuable information about pathways to human tolerance. Recent evidence indicates that B regulatory (Breg) cells play a pivotal role in controlling the production of antibodies (Abs) while promoting follicular T helper (Tfh) cells and monocytes, expressing the low-density lipoprotein receptor-related protein (LRP/CD91), which is involved in FVIII intake from the circulation. We studied circulating levels of Breg cells along with Tfh cells and the expression of LRP/CD91 on monocytes in patients with hemophilia A using 8-color flow cytometry and cell culture. Compared to healthy controls, patients with hemophilia A with inhibitors showed a severe reduction in levels of Breg cells and produced less interleukin-10 when activated via the CD40 signaling pathway. In addition, patients with hemophilia A with inhibitors exhibited an overexpression of LPR/CD91 on monocytes and normal levels of Tfh cells. Levels of Breg cells were not significantly related to LPR/CD91 although negative associations were evidenced. Collectively, these results provide new insights into the role of Breg cells and LPR/CD91 in the development of inhibitors in patients with hemophilia A.
Oman Medical Journal | 2017
Amal Al Maani; Abdullah Al Qayoudhi; Hanan Nazir; Heba Omar; Amina Al Jardani; Zakariya Al Muharrmi; Yasser Wali
OBJECTIVES A resurgence of pertussis or whooping cough has been observed worldwide despite broad vaccination coverage. Pertussis like illness (PLI) refers to a clinical syndrome compatible with pertussis infection but lacking laboratory confirmation or an epidemiological link to a confirmed case. Our study aimed to estimate the contribution of Bordetella pertussis infection and identifying predictors of its diagnosis in a cohort of children with PLI. METHODS Demographic and clinical information were retrospectively collected from the medical records of children < 13 years old and hospitalized for PLI in two pediatric units in Oman from 1 January 2012 to 31 December 2013. The laboratory data of all cases were reviewed and confirmed cases of pertussis were identified, analyzed, and compared with non-confirmed cases. RESULTS A total of 131 patients were enrolled in this study. The majority (95.4% [125/131]) were infants. Only 54.1% (71/131) of admitted children with PLI were tested for pertussis. The incidence of pertussis infection among the tested group was 16.9% (12/71) with a 95% confidence interval 8.2-25.6. Severe illness occurred in 56.4% (74/131) of patients, and six were confirmed to have pertussis. Pediatric intensive care unit admission was required for one confirmed case of pertussis and eight cases from the PLI group (three were negative for pertussis, and five were not tested). Receiver operator characteristic curve analysis revealed that a white blood cell count 3 23.5 × 109/L had 96.6% specificity and lymphocytes 3 17 × 109/L had 98.3% specificity. CONCLUSIONS Taking into consideration that the number tested for pertussis was limited, the incidence of pertussis was 16.9% (12 out of 71 patients). Lymphocytosis can be used as a reliable predictor for the diagnosis of pertussis especially in the absence of specific confirmatory tests or until their results are available.
Hematology & Transfusion International Journal | 2017
Yasser Wali; Halima AlBalushi; Hanan Nazir
Hematol Transfus Int J 2017, 4(6): 00100 complications contribute to a high mortality of SCD patients, especially before seven years of age in areas with poor healthcare. SCD is also associated with a poor quality of life and severe organ damage [5]. Moreover, treatment of SCD is still only supportive, employing periodic blood exchange transfusions and hydroxyurea (HU), which is the only US Food and Drug Administration (FDA) approved SCD therapy [6].
Hematology & Transfusion International Journal | 2018
Hanan Nazir
55th Annual ESPE | 2016
Anwar Alomairi; Sharef Almullabd; Doaa Khater; Saif Al-Yaarubi; Hanan Nazir; Yasser Wali
Blood | 2014
Hanan Nazir; Tuqa Allawati; Ismail Elbeshlawi; Murtadha Al-Khabori; Sara Al-Kindi; Wafa Alriyami; Yasser Wali
Blood | 2014
Hanan Nazir; Murtadha Al-Khabori; Naschla Kohistani; Jacek Puchałka; Christoph Klein
Blood | 2014
Surekha Tony Mevada; Abdaluziz Sulieman AlDhuli; A.Hakim Al-Rawas; Murtadha Al-Khabori; Hanan Nazir; Mathew Zachariah; Yasser Wali